Author: "Delaporte, E." / Topic: hiv - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Delaporte, E."' showing total 21 results

Start Over Author "Delaporte, E." Topic hiv

21 results on '"Delaporte, E."'

1. Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo.

Author: Konou AA, Dagnra AY, Vidal N, Salou M, Adam Z, Singo-Tokofai A, Delaporte E, Prince-David M, and Peeters M
Subjects: Adult, Cross-Sectional Studies, Female, HIV isolation & purification, Humans, Male, Middle Aged, Prevalence, Togo epidemiology, Viral Load, Anti-HIV Agents therapeutic use, Drug Resistance, Viral, HIV drug effects, HIV Infections drug therapy, HIV Infections virology
Abstract: Information on efficacy of long-term antiretroviral treatment (ART) exposure in resource-limited countries is still scarce. In 767 patients attending routine HIV centers in Togo and receiving first-line ART for more than four years, 42% had viral load greater than 1000 copies/ml and either were on a completely ineffective ART regime or were with only a single drug active. The actual conditions to ensure lifelong ART in resource-limited countries can have dramatic long-term outcomes.
Published: 2015
Full Text: View/download PDF

2. Susceptibility to transmitting HIV in patients initiating antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial).

Author: Ndziessi G, Cohen J, Kouanfack C, Marcellin F, Carrieri MP, Laborde-Balen G, Protopopescu C, Aghokeng AF, Moatti JP, Spire B, Delaporte E, Laurent C, and Boyer S
Subjects: Adult, Cameroon epidemiology, Condoms, Female, HIV Infections epidemiology, Hospitals, District, Humans, Male, Risk Factors, Safe Sex drug effects, Sexual Partners, Anti-Retroviral Agents therapeutic use, HIV drug effects, HIV pathogenicity, HIV Infections drug therapy, HIV Infections transmission
Abstract: Objectives: Using cohort data nested in a randomized trial conducted in Cameroon, this study aimed to investigate time trends and predictors of the susceptibility to transmitting HIV during the first 24 months of treatment., Methods: The outcome, susceptibility to transmitting HIV, was defined as reporting inconsistent condom use and experiencing incomplete virological suppression. Mixed logistic regressions were performed to identify predictors of this outcome among 250 patients reporting to have had sexual relationships either with HIV-negative or unknown HIV status partner(s)., Results: Despite an initial decrease from 76% at M0 to 50% at M6, the rate of inconsistent condom use significantly increased from M12 (59%) to M24 (66%) (p = 0.017). However, the proportion of patients susceptible to transmitting HIV significantly decreased over follow-up from 76% at M0, to 50% at M6, 31% at M12 and 27% at M24 (p<0.001). After controlling for age, gender and intervention group, we found that perceiving healthcare staff's readiness to listen as poor (adjusted odds ratios (AOR) [95% Confidence Interval (CI)] = 1.87 [1.01-3.46]), reporting to have sexual relationships more than once per week (AOR [95%CI] = 2.52 [1.29-4.93]), having more than one sexual partner (AOR [95%CI] = 2.53 [1.21-5.30]) and desiring a/another child (AOR [95%CI] = 2.07 [1.10-3.87]) were all associated with a higher risk of being susceptible to transmitting HIV. Conversely, time since ART initiation (AOR [95%CI] = 0.66 [0.53-0.83] for an extra 6 months and ART adherence (AOR [95%CI] = 0.33 [0.15-0.72]) were significantly associated with a lower risk of being susceptible to transmitting HIV., Conclusions: The decrease observed in the susceptibility to transmitting HIV suggests that fear of behavioural disinhibition should not be a barrier to universal access to ART. However, developing adequate preventive interventions matching patients' expectations -like the desire to have children- and strengthening healthcare staff's counselling skills are urgently needed to maximize the impact of ART in slowing the HIV epidemic.
Published: 2013
Full Text: View/download PDF

3. Task shifting HIV care in rural district hospitals in Cameroon: evidence of comparable antiretroviral treatment-related outcomes between nurses and physicians in the Stratall ANRS/ESTHER trial.

Author: Boullé C, Kouanfack C, Laborde-Balen G, Carrieri MP, Dontsop M, Boyer S, Aghokeng AF, Spire B, Koulla-Shiro S, Delaporte E, and Laurent C
Subjects: Adult, CD4 Lymphocyte Count, Cameroon epidemiology, Cohort Studies, Female, HIV Infections epidemiology, HIV Infections virology, Hospitals, Rural, Humans, Male, Nurses, Physicians, Regression Analysis, Rural Population, Young Adult, Anti-HIV Agents administration & dosage, HIV isolation & purification, HIV Infections drug therapy
Abstract: Background: Task shifting to nurses for antiretroviral therapy (ART) is promoted by the World Health Organization to compensate for the severe shortage of physicians in Africa. We assessed the effectiveness of task shifting from physicians to nurses in rural district hospitals in Cameroon., Methods: We performed a cohort study using data from the Stratall trial, designed to assess monitoring strategies in 2006-2010. ART-naive patients were followed up for 24 months after treatment initiation. Clinical visits were performed by nurses or physicians. We assessed the associations between the consultant ratio (ie, the ratio of the number of nurse-led visits to the number of physician-led visits) and HIV virological success, CD4 recovery, mortality, and disease progression to death or to the World Health Organization clinical stage 4 in multivariate analyses., Results: Of the 4141 clinical visits performed in 459 patients (70.6% female, median age 37 years), a quarter was task shifted to nurses. The consultant ratio was not significantly associated with virological success [odds ratio 1.00, 95% confidence interval (CI): 0.59 to 1.72, P = 0.990], CD4 recovery (coefficient -3.6, 95% CI: -35.6; 28.5, P = 0.827), mortality (time ratio 1.39, 95% CI: 0.27 to 7.06, P = 0.693), or disease progression (time ratio 1.60, 95% CI: 0.35 to 7.37, P = 0.543)., Conclusions: This study brings important evidence about the comparability of ART-related outcomes between HIV models of care based on physicians or nurses in resource-limited settings. Investing in nursing resources for the management of noncomplex patients should help reduce costs and patient waiting lists while freeing up physician time for the management of complex cases, for mentoring and supervision activities, and for other health interventions.
Published: 2013
Full Text: View/download PDF

4. Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis.

Author: Bastard M, Fall MB, Lanièce I, Taverne B, Desclaux A, Ecochard R, Sow PS, Delaporte E, and Etard JF
Subjects: Adult, Antiretroviral Therapy, Highly Active psychology, Antiretroviral Therapy, Highly Active standards, CD4 Lymphocyte Count, Cohort Studies, Female, HIV Infections immunology, HIV Infections psychology, Humans, Male, Senegal, Survival Analysis, Anti-HIV Agents administration & dosage, Antiretroviral Therapy, Highly Active methods, HIV isolation & purification, HIV Infections drug therapy, Patient Compliance
Abstract: Background: Adherence is one of the main predictors of antiretroviral treatment success. A governmental initiative was launched in 1998 for HIV-infected patients in Senegal to provide access to highly active antiretroviral therapy., Methods: Between August 1998 and April 2002, 404 adult patients were enrolled. Adherence measurements, defined as pills taken/pills prescribed, were assessed between November 1999 and April 2009 using a pill count along with a questionnaire for 330 patients. Predictors of adherence were explored through a random-intercept Tobit model and a latent class analysis (LCA) was performed to identify adherence trajectories. We also performed a survival analysis taking into account gender and latent adherence classes., Results: Median treatment duration was 91 months (interquartile range, 84-101). On average, adherence declined by 7% every year, was 30% lower for patients taking indinavir, and 12% higher for those receiving cotrimoxazole prophylaxis. Based on the predicted probability of having an adherence ≥ 95%, LCA revealed 3 adherence behaviors and a better adherence for women. A quarter of patients had a high adherence trajectory over time and half had an intermediate one. Male gender and low adherence behavior over time were independently associated with a higher mortality rate., Conclusions: This study shows that an overall good adherence can be obtained in the long term in Senegal. LCA suggests a better adherence for women and points out a large subsample of patients with intermediate level of adherence behavior who are at risk for developing resistance to antiretroviral drugs. This study warrants further research into gender issues.
Published: 2011
Full Text: View/download PDF

5. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.

Author: Cournil A, Coudray M, Kouanfack C, Essomba CN, Tonfack CA, Biwolé-Sida M, Delaporte E, Bork K, and Laurent C
Subjects: Adult, Anti-HIV Agents adverse effects, CD4 Lymphocyte Count, Cameroon, Cross-Sectional Studies, Female, Humans, Lamivudine administration & dosage, Lamivudine adverse effects, Male, Middle Aged, Nevirapine administration & dosage, Nevirapine adverse effects, Stavudine adverse effects, Zidovudine administration & dosage, Zidovudine adverse effects, Anti-HIV Agents administration & dosage, HIV drug effects, HIV Infections drug therapy, Lipodystrophy metabolism, Stavudine administration & dosage
Abstract: Background: This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment., Methods: A total of 243 patients from Cameroon receiving d4T or zidovudine (AZT) in combination with lamivudine and efavirenz or nevirapine for >6 months were clinically assessed for moderate to severe ('strict' definition) and mild to severe ('large' definition) lipoatrophy. Prevalence of lipoatrophy was compared between 69 patients who had received exclusively d4T 30 mg (d4T(30)), 64 patients who had received both d4T 30 and 40 mg dosages since treatment initiation (d4T(30/40)) and 110 patients on AZT-related therapy., Results: Prevalence of lipoatrophy varied from 7% to 24%, according to the definition. After adjustment for gender, age, treatment duration and CD4(+) T-cell count, the risk of lipoatrophy in the d4T(30) group was lower than in the d4T(30/40) group (odds ratio [OR] 0.3, 95% confidence interval [CI] 0.1-0.8 with the large definition and OR 0.2, 95% CI 0.0-0.8 with the strict definition) and was comparable to that of the AZT group (OR 1.0, 95% CI 0.2-4.6 and OR 1.0, 95% CI 0.4-2.2 with the large and strict definitions, respectively). The risk was significantly higher in the d4T(30/40) group compared with the AZT group (OR 2.9, 95% CI 1.3-6.4 with the large definition and OR 5.5, 95% CI 1.3-23.5 with the strict definition)., Conclusions: The use of d4T at a lower dosage might increase safety with regard to its effect on lipoatrophy.
Published: 2010
Full Text: View/download PDF

6. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment.

Author: Kouanfack C, Montavon C, Laurent C, Aghokeng A, Kenfack A, Bourgeois A, Koulla-Shiro S, Mpoudi-Ngole E, Peeters M, and Delaporte E
Subjects: Adult, Anti-HIV Agents pharmacology, Cameroon, Cross-Sectional Studies, Female, Guideline Adherence, HIV isolation & purification, Humans, Male, Middle Aged, Treatment Outcome, Anti-HIV Agents therapeutic use, Drug Resistance, Viral, HIV drug effects, HIV Infections drug therapy, HIV Infections virology
Abstract: A cross-sectional study, performed at a routine human immunodeficiency virus (HIV)/AIDS clinic in Cameroon that uses the World Health Organization public health approach, showed low rates of virological failure and drug resistance at 12 and 24 months after initiation of antiretroviral therapy. Importantly, the cross-sectional study also showed that the World Health Organization recommendation for second-line treatment would be effective in almost all patients with HIV drug resistance mutations.
Published: 2009
Full Text: View/download PDF

7. Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002.

Author: Vidal N, Mulanga C, Bazepeo SE, Mwamba JK, Tshimpaka JW, Kashi M, Mama N, Laurent C, Lepira F, Delaporte E, and Peeters M
Subjects: Adult, Democratic Republic of the Congo, Female, Genes, env, Genetic Variation, Genotype, Geography, HIV isolation & purification, HIV Envelope Protein gp120 genetics, Humans, Male, Molecular Epidemiology, Molecular Sequence Data, Phylogeny, Recombination, Genetic, Sequence Analysis, DNA, Sequence Homology, HIV classification, HIV genetics, HIV Infections virology
Abstract: The Democratic Republic of Congo (DRC) is characterized by low and stable HIV prevalences and high HIV-1 genetic diversity and is most probably the epicenter of HIV-1 group M. Our major goal was to study the distribution of HIV-1 variants over a 5-year period against a background of political instability and civil war. A total of 288 HIV-1-positive samples collected in 2002 from sentinel population groups in an HIV serosurveillance study performed in 4 cities (Kinshasa [capital city], Mbuji-Mayi [south], Lubumbashi [southeast], and Kisangani [northeast]) were genetically characterized by sequencing and phylogenetic analysis of the V3-V5 env region. The results were compared with those obtained in 1997. Similarly, as in 1997, an extremely high genetic diversity of HIV-1 strains overall and a heterogeneous geographic distribution were seen in 2002. All subtypes and several circulating recombinant forms were present, high intrasubtype diversity was observed, and 5.6% of the samples could not be classified. In each geographic region of the DRC, the genetic diversity was significantly higher than in neighboring countries. Comparison of subtype distribution in similar population groups in Kinshasa in 1997 and 2002 revealed an overall increase of subtype C in Kinshasa from 2.1% to 9.7% and, more precisely, from 0% to 18.9% in female sex workers (P = 0.013). Genetic characterization of HIV-positive samples from sentinel surveys adds significant additional information on new trends in the HIV epidemic. These changes could have implications regarding the spread of HIV infection in the DRC as well on vaccine and/or treatment strategies.
Published: 2005
Full Text: View/download PDF

8. [Prevalence of hepatitis B and C virus, HTLV-1 and HIV in type B lymphoproliferative syndromes in Gabon].

Author: Perret JL, Moussavou-Kombila JB, Delaporte E, Minko-Mi-Etoua D, Pemba LF, Boguikouma JB, Nzenze JR, Deparis X, and Larouzé B
Subjects: Adolescent, Adult, Aged, Antibodies, Viral blood, Female, Gabon, HIV immunology, Hepacivirus immunology, Hepatitis B Surface Antigens blood, Hepatitis B virus immunology, Human T-lymphotropic virus 1 immunology, Humans, Leukemia, Lymphocytic, Chronic, B-Cell virology, Lymphoma virology, Male, Middle Aged, HIV isolation & purification, Hepacivirus isolation & purification, Hepatitis B virus isolation & purification, Human T-lymphotropic virus 1 isolation & purification, Lymphoproliferative Disorders virology
Abstract: B lymphoproliferative disorders (B-LPD) are the most frequent types of lymphoid malignancies encountered in Gabon where HCV, HBV, HTLV-I and HIV are highly prevalent and all known for lymphotropism. Prevalences of HBs Ag, antibodies to HCV, HTLV-I and HIV were compared in 40 patients (21 men, 19 women; 17 < age < 75 years) with newly diagnosed B-LPD (low grade lymphoma = 6, intermediate grade = 21, high grade = 8: chronic lymphocytic leukaemia = 5) and 160 age and sex-matched controls. None of the B-LPD patients had got transfusion or parenteral care from the onset of symptoms to the inclusion day. In the B-LPD group, 13 patients had HBs Ag and antibodies to HCV, HIV and HTLV-1 were detected in 11, 6 and 10 subjects. In monovariate analysis, HBs Ag, antibodies to HIV or HTLV-1 were risk factors for B-LPD but antibodies to HCV were not associated with such diseases. Multivariate analysis showed only a relationship between HBs Ag and B-LPD (OR = 3.86; IC: 1.11-13.48). In such patients, reactivation of B hepatitis by treatment of B-LBD may be an important concern. If a background poor immune system could explain both susceptibility to long standing virus carriage and lymphoma development, a participating action of the HBV in lymphomagenesis could not be excluded.
Published: 2003

9. Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny.

Author: Courgnaud V, Salemi M, Pourrut X, Mpoudi-Ngole E, Abela B, Auzel P, Bibollet-Ruche F, Hahn B, Vandamme AM, Delaporte E, and Peeters M
Subjects: Amino Acid Sequence, Animals, Antibodies, Viral blood, Base Sequence, Cameroon, Cross Reactions, Genes, env, Genome, Viral, HIV classification, HIV immunology, HIV Antibodies blood, Humans, Molecular Sequence Data, Nucleic Acid Conformation, Phylogeny, RNA, Viral chemistry, RNA, Viral genetics, Recombination, Genetic, Sequence Homology, Amino Acid, Simian Immunodeficiency Virus classification, Simian Immunodeficiency Virus immunology, Species Specificity, Cercopithecus virology, Genes, vpu, HIV genetics, Simian Immunodeficiency Virus genetics, Simian Immunodeficiency Virus isolation & purification
Abstract: In the present study, we describe a new simian immunodeficiency virus (SIV), designated SIVgsn, naturally infecting greater spot-nosed monkeys (Cercopithecus nictitans) in Cameroon. Together with SIVsyk, SIVgsn represents the second virus isolated from a monkey belonging to the Cercopithecus mitis group of the Cercopithecus genus. Full-length genome sequence analysis of two SIVgsn strains, SIVgsn-99CM71 and SIVgsn-99CM166, revealed that despite the close phylogenetic relationship of their hosts, SIVgsn was highly divergent from SIVsyk. First of all, they differ in their genomic organization. SIVgsn codes for a vpu homologue, so far a unique feature of the members of the SIVcpz/human immunodeficiency virus type 1 (HIV-1) lineage, and detailed phylogenetic analyses of various regions of the viral genome indicated that SIVgsn might be a mosaic of sequences with different evolutionary histories. SIVgsn was related to SIVsyk in Gag and part of Pol and related to SIVcpz in Env, and the middle part of the genome did not cluster significantly with any of the known SIV lineages. When comparing the two SIVgsn Env sequences with that of SIVcpz, a remarkable conservation was seen in the V3 loop, indicating a possible common origin for the envelopes of these two viruses. The habitats of the two subspecies of chimpanzees infected by SIVcpz overlap the geographic ranges of greater spot-nosed monkeys and other monkey species, allowing cross-species transmission and recombination between coinfecting viruses. The complex genomic structure of SIVgsn, the presence of a vpu gene, and its relatedness to SIVcpz in the envelope suggest a link between SIVgsn and SIVcpz and provide new insights about the origin of SIVcpz in chimpanzees.
Published: 2002
Full Text: View/download PDF

10. Reactivities of antibodies to HIV and SIV in human sera in Kenya, Gabon, and Ghana.

Author: Masuda T, Tsujimoto H, Ishikawa K, Ohta Y, Hayami M, Ocheng EM, Johnson BK, Tukei PM, Delaporte E, and Cooper RW
Subjects: Acquired Immunodeficiency Syndrome transmission, Gabon, Ghana, Humans, Japan, Kenya, Sex Work, Acquired Immunodeficiency Syndrome immunology, Antibodies, Viral immunology, HIV immunology, Retroviridae immunology, Retroviridae Infections immunology
Published: 1988
Full Text: View/download PDF

11. Impact à long terme des traitements antirétroviraux en Afrique, état des connaissances

Author: Taverne, B., Desclaux, A., Delaporte, E., and Ndoye, I.
Published: 2014
Full Text: View/download PDF

12. Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

Author: Liégeois, Florian, Boyer, S., Eymard-Duvernay, Sabrina, Carrieri, P., Kouanfack, C., Domyeum, J., Maradan, G., Ducos, J., Mpoudi-Ngole, E., Spire, B., Delaporte, E., Kuaban, C., Vidal, Laurent, Laurent, Christian, and EVOLCAM Study Group
Subjects: Treatment, Africa, Testing, HBV, virus diseases, HIV, lcsh:RC109-216, lcsh:Infectious and parasitic diseases
Abstract: Background Hepatitis B is a major concern in Africa, especially in HIV-infected patients. Unfortunately, access to hepatitis B virus (HBV) testing and adequate treatment remains a challenge in the continent. We investigated HBV testing, treatment, and virologic suppression in HIV-infected patients followed up as part of Cameroon’s national antiretroviral programme. Methods A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in 19 hospitals in the Centre and Littoral regions in Cameroon. The proportions of patients tested for hepatitis B surface antigen (HBsAg) prior to the study were compared among all study hospitals using the Chi-square test. The association of individual and hospital-related characteristics with HBV testing and virologic suppression was assessed using multilevel logistic regression models. Results Of 1706 patients (women 74%, median age 42 years, median time on ART 3.9 years), 302 (17.7%) had been tested for HBsAg prior to the study. The proportion of HBV-tested patients ranged from 0.8 to 72.5% according to the individual hospital (p
Published: 2020

13. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018

Author: Pradat, Pierre, Chirouze, C, Drobacheff-Thiébaut, C, Foltzer, A, Bouiller, K, Hustache-Mathieu, L, Lepiller, Q, Bozon, F, Babre, O, Brunel, A, Muret, P, Chevalier, E, Jacomet, C, Laurichesse, H, LESENS, O, Vidal, M, Mrozek, N, Aumeran, C, Baud, O, Corbin, V, Goncalvez, E, Mirand, A, brebion, A, Henquell, C, Lamaury, I, Fabre, I, Curlier, E, Ouissa, R, Herrmann-Storck, C, Tressieres, B, Receveur, M, Boulard, F, Daniel, C, CLAVEL, C, Roger, P, Markowicz, S, Chellum Rungen, N, Merrien, D, Perré, P, Guimard, T, Bollangier, O, Leautez, S, Morrier, M, Laine, L, Boucher, D, Point, P, Cotte, Laurent, Ader, F, Becker, A, Boibieux, A, Brochier, C, Brunel-Dalmas, F, Cannesson, O, Chiarello, P, Chidiac, C, Degroodt, S, FERRY, T, Godinot, M, Livrozet, J, Makhloufi, D, Miailhes, P, Perpoint, T, Perry, M, Pouderoux, C, Roux, Stéphane, Triffault-Fillit, C, Valour, F, Charre, C, Icard, V, Tardy, J, Trabaud, M, Ravaux, I, Ménard, A, Belkhir, A, Colson, P, Dhiver, C, Madrid, A, Martin-Degioanni, M, Meddeb, L, Mokhtari, M, Motte, A, Raoux, A, Toméi, C, Tissot-Dupont, H, Poizot-Martin, Isabelle, Brégigeon, S, Zaegel-Faucher, O, Obry-Roguet, V, Laroche, H, Orticoni, M, Soavi, M, Ressiot, E, Ducassou, M, Jaquet, I, Galie, S, Colson, H, Ritleng, A, Ivanova, A, Debreux, C, Lions, C, Rojas-Rojas, T, Cabié, André, Abel, S, Bavay, J, Bigeard, B, Cabras, O, Cuzin, L, Dupin de Majoubert, R, Fagour, L, Guitteaud, K, Marquise, A, Najioullah, F, Pierre-François, S, Pasquier, J, Richard, P, Rome, K, Turmel, J, Varache, C, Atoui, N, Bistoquet, M, Delaporte, E, Le Moing, V, Makinson, A, Meftah, N, Merle de Boever, C, Montes, B, Montoya Ferrer, A, Tuaillon, E, Reynes, J, Lefèvre, B, Jeanmaire, E, Hénard, S, Frentiu, E, Charmillon, A, Legoff, A, Tissot, N, André, M, Boyer, L, Bouillon, M, Delestan, M, Goehringer, F, Bevilacqua, S, Rabaud, C, May, T, Raffi, F, Allavena, C, Aubry, O, Billaud, E, Biron, C, Bonnet, B, Bouchez, S, Boutoille, D, Brunet-Cartier, C, Deschanvres, C, Gaborit, B, Grégoire, A, Grégoire, M, Grossi, O, Guéry, R, Lefebvre, Maeva, Le Turnier, P, Lecomte, R, Morineau, P, Reliquet, V, Sécher, S, Cavellec, M, Paredes, E, Soria, A, Ferré, V, André-Garnier, E, Rodallec, A, Pugliese, Pascal, Breaud, S, Ceppi, C, Chirio, D, Cua, E, Dellamonica, P, Demonchy, E, De Monte, A, Durant, J, Etienne, C, Ferrando, S, Garraffo, R, Michelangeli, C, Mondain, V, Naqvi, A, Oran, N, Perbost, I, Carles, M, Klotz, C, Maka, A, Pradier, C, Prouvost-Keller, B, Risso, K, Rio, V, Rosenthal, E, Touitou, I, Wehrlen-Pugliese, S, Zouzou, G, Hocqueloux, Laurent, Prazuck, T, Gubavu, C, Sève, A, Giaché, S, Rzepecki, V, Colin, M, Boulard, C, Thomas, G, Cheret, A, Goujard, C, Quertainmont, Y, Teicher, E, Lerolle, N, Jaureguiberry, S, Colarino, R, Deradji, O, Castro, A, Barrail-Tran, A, Yazdanpanah, Y, Landman, R, Joly, V, Ghosn, J, Rioux, C, Lariven, S, gervais, a, Lescure, F, Matheron, S, Louni, F, Julia, Z, Le Gac, S, Charpentier, c, Descamps, D, Peytavin, G, Duvivier, C, Aguilar, C, Alby-Laurent, F, Amazzough, K, Benabdelmoumen, G, Bossi, P, Cessot, G, Charlier, C, Consigny, P, Jidar, K, Lafont, E, Lanternier, F, Leporrier, J, Lortholary, O, Louisin, C, Lourenco, J, Parize, P, Pilmis, B, Rouzaud, C, Touam, F, Valantin, M, Tubiana, R, Agher, R, Seang, S, Schneider, L, PaLich, R, Blanc, C, Katlama, C, Bani-Sadr, Firouze, Berger, J, N’Guyen, Y, Lambert, D, Kmiec, I, Hentzien, M, Brunet, A, Romaru, J, Marty, H, Brodard, V, Arvieux, C, Tattevin, P, Revest, M, Souala, F, Baldeyrou, M, Patrat-Delon, S, Chapplain, J, Benezit, F, Dupont, M, Poinot, M, MAILLARD, A, Pronier, C, Lemaitre, F, Morlat, C, Poisson-Vannier, M, Jovelin, T, Sinteff, J, Gagneux-Brunon, A, Botelho-Nevers, E, Frésard, A, Ronat, V, Lucht, F, Rey, David, Fischer, P, Partisani, M, Cheneau, C, Priester, M, Mélounou, C, Bernard-Henry, C, de Mautort, E, Fafi-Kremer, S, Delobel, P, Alvarez, M, Biezunski, N, Debard, A, Delpierre, C, Gaube, G, Lansalot, P, Lelièvre, L, Marcel, M, Martin-Blondel, G, Piffaut, M, Porte, L, Saune, K, Robineau, O, Ajana, F, Aïssi, E, Alcaraz, I, Alidjinou, E, Baclet, V, Bocket, L, Boucher, A, Digumber, M, Huleux, Thomas, Lafon-Desmurs, B, Meybeck, A, Pradier, M, Tetart, M, Thill, P, Viget, N, Valette, M, Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Université des Antilles (UA)-Etablissement français du don du sang [Montpellier]-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional d'Orléans (CHRO), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital universitaire Robert Debré [Reims], Centre Hospitalier Gustave Dron [Tourcoing], Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Aix Marseille Université (AMU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital l'Archet, Les Hôpitaux Universitaires de Strasbourg (HUS), Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Université des Antilles (UA), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Dat’AIDS Study Group Besançon: C. Chirouze, C. Drobacheff-Thiébaut, A. Foltzer, K. Bouiller, L. Hustache- Mathieu, Q. Lepiller, F. Bozon, O. Babre, AS. Brunel, P. Muret, E. Chevalier. Clermont-Ferrand: C. Jacomet, H. Laurichesse, O. Lesens, M. Vidal, N. Mrozek, C. Aumeran, O. Baud, V. Corbin, E. Goncalvez, A Mirand, A brebion, C Henquell. Guadeloupe: I. Lamaury, I. Fabre, E. Curlier, R. Ouissa, C. Herrmann-Storck, B. Tressieres, MC. Receveur, F. Boulard, C. Daniel, C. Clavel, PM. Roger, S. Markowicz, N. Chellum Rungen. La Roche sur Yon: D. Merrien, P. Perré, T. Guimard, O. Bollangier, S. Leautez, M. Morrier, L. Laine, D. Boucher, P. Point. Lyon: L. Cotte, F. Ader, A. Becker, A. Boibieux, C. Brochier F, Brunel-Dalmas, O. Cannesson, P. Chiarello, C. Chidiac, S. Degroodt, T. Ferry, M. Godinot, J.M. Livrozet, D. Makhloufi, P. Miailhes, T. Perpoint, M. Perry, C. Pouderoux, S. Roux, C. Triffault-Fillit, F. Valour, C. Charre, V. Icard, J.C. Tardy, M.A. Trabaud. Marseille IHU Méditerrannée: I. Ravaux, A. Ménard, AY. Belkhir, P. Colson, C. Dhiver, A. Madrid, M. Martin-Degioanni, L. Meddeb, M. Mokhtari, A. Motte, A. Raoux, C. Toméi, H. Tissot-Dupont. Marseille Ste Marguerite: I. Poizot-Martin, S. Brégigeon, O. Zaegel-Faucher, V. Obry-Roguet, H Laroche, M. Orticoni, M.J. Soavi, E. Ressiot, M.J. Ducassou, I. Jaquet, S. Galie, H. Colson, A.S. Ritleng, A. Ivanova, C. Debreux, C. Lions, T Rojas-Rojas. Martinique: A. Cabié, S. Abel, J. Bavay, B. Bigeard, O. Cabras, L. Cuzin, R. Dupin de Majoubert, L. Fagour, K. Guitteaud, A. Marquise, F. Najioullah, S. Pierre-François, J. Pasquier, P. Richard, K. Rome, JM Turmel, C. Varache. Montpellier: N. Atoui, M. Bistoquet, E Delaporte, V. Le Moing, A. Makinson, N. Meftah, C. Merle de Boever, B. Montes, A. Montoya Ferrer, E. Tuaillon, J. Reynes. Nancy: B. Lefèvre, E. Jeanmaire, S. Hénard, E. Frentiu, A. Charmillon, A. Legoff, N. Tissot, M. André, L. Boyer, MP. Bouillon, M. Delestan, F. Goehringer, S. Bevilacqua, C. Rabaud, T. May. Nantes: F. Raffi, C. Allavena, O. Aubry, E. Billaud, C. Biron, B. Bonnet, S. Bouchez, D. Boutoille, C. Brunet-Cartier, C. Deschanvres, B.J. Gaborit, A. Grégoire, M. Grégoire, O. Grossi, R. Guéry, T. Jovelin, M. Lefebvre, P. Le Turnier, R. Lecomte, P. Morineau, V. Reliquet, S. Sécher, M. Cavellec, E. Paredes, A. Soria, V. Ferré, E. André-Garnier, A. Rodallec. Nice: P. Pugliese, S. Breaud, C. Ceppi, D. Chirio, E. Cua, P. Dellamonica, E. Demonchy, A. De Monte, J. Durant, C. Etienne, S. Ferrando, R. Garraffo, C. Michelangeli, V. Mondain, A. Naqvi, N. Oran, I. Perbost, M. Carles, C. Klotz, A. Maka, C. Pradier, B. Prouvost- Keller, K. Risso, V. Rio, E. Rosenthal, I. Touitou, S. Wehrlen-Pugliese, G. Zouzou. Orléans: L. Hocqueloux, T. Prazuck, C. Gubavu, A. Sève, S. Giaché, V. Rzepecki, M. Colin, C. Boulard, G. Thomas. Paris APHP Bicètre: A. Cheret, C. Goujard, Y. Quertainmont, E. Teicher, N. Lerolle, S. Jaureguiberry, R. Colarino, O. Deradji, A. Castro, A. Barrail-Tran. Paris APHP Bichat: Y. Yazdanpanah, R. Landman, V. Joly, J. Ghosn, C. Rioux, S. Lariven, A. Gervais, FX. Lescure, S. Matheron, F. Louni, Z. Julia, S. Le GAC, C. Charpentier, D. Descamps, G. Peytavin. Paris APHP Necker Pasteur: C. Duvivier, C. Aguilar, F. Alby-Laurent, K. Amazzough, G. Benabdelmoumen, P. Bossi, G. Cessot, C. Charlier, P.H. Consigny, K. Jidar, E. Lafont, F. Lanternier, J. Leporrier, O. Lortholary, C. Louisin, J. Lourenco, P. Parize, B. Pilmis, C. Rouzaud, F. Touam. Paris APHP Pitié Salpetrière: MA. Valantin, R. Tubiana, R. Agher, S. Seang, L. Schneider, R. PaLich, C. Blanc, C. Katlama. Reims: F. Bani-Sadr, JL. Berger, Y. N’Guyen, D. Lambert, I. Kmiec, M. Hentzien, A. Brunet, J. Romaru, H. Marty, V. Brodard. Rennes: C. Arvieux, P. Tattevin, M. Revest, F. Souala, M. Baldeyrou, S. Patrat-Delon, J.M. Chapplain, F. Benezit, M. Dupont, M. Poinot, A. Maillard, C. Pronier, F. Lemaitre, C. Morlat, M. Poisson-Vannier, T. Jovelin, JP. Sinteff. St Etienne: A. Gagneux-Brunon, E. Botelho-Nevers, A. Frésard, V. Ronat, F. Lucht. Strasbourg: D. Rey, P. Fischer, M. Partisani, C. Cheneau, M. Priester, C. Mélounou, C. Bernard-Henry, E. de Mautort, S. Fafi-Kremer. Toulouse: P. Delobel, M. Alvarez, N. Biezunski, A. Debard, C. Delpierre, G. Gaube, P. Lansalot, L. Lelièvre, M. Marcel, G. Martin-Blondel, M. Piffaut, L. Porte, K. Saune. Tourcoing: O. Robineau, F. Ajana, E. Aïssi, I. Alcaraz, E. Alidjinou, V. Baclet, L. Bocket, A. Boucher, M. Digumber, T. Huleux, B. Lafon-Desmurs, A. Meybeck, M. Pradier, M. Tetart, P. Thill, N. Viget, M. Valette., CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles et de la Guyane (UAG), and Malbec, Odile
Subjects: Microbiology (medical), Male, medicine.medical_specialty, Hepatitis C virus, [SDV]Life Sciences [q-bio], Population, men having sex with men, HIV Infections, Hepacivirus, medicine.disease_cause, Antiviral Agents, Men who have sex with men, 03 medical and health sciences, Sexual and Gender Minorities, 0302 clinical medicine, Internal medicine, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Human Immunodeficiency virus, Homosexuality, Male, education, Retrospective Studies, Hepatitis, education.field_of_study, business.industry, Coinfection, Mortality rate, Incidence (epidemiology), microelimination, virus diseases, HIV, Hepatitis C, Chronic, medicine.disease, Hepatitis C, digestive system diseases, 3. Good health, [SDV] Life Sciences [q-bio], Infectious Diseases, Cohort, 030211 gastroenterology & hepatology, epidemiology, France, business
Abstract: Background The arrival of highly effective, well-tolerated, direct-acting antiviral agents (DAA) led to a dramatic decrease in hepatitis C virus (HCV) prevalence. Human immunodeficiency virus (HIV)-HCV–coinfected patients are deemed a priority population for HCV elimination, while a rise in recently acquired HCV infections in men who have sex with men (MSM) has been described. We describe the variations in HIV-HCV epidemiology in the French Dat’AIDS cohort. Methods This was a retrospective analysis of a prospective cohort of persons living with HIV (PLWH) from 2012 to 2018. We determined HCV prevalence, HCV incidence, proportion of viremic patients, treatment uptake, and mortality rate in the full cohort and by HIV risk factors. Results From 2012 to 2018, 50 861 PLWH with a known HCV status were followed up. During the period, HCV prevalence decreased from 15.4% to 13.5%. HCV prevalence among new HIV cases increased from 1.9% to 3.5% in MSM but remained stable in other groups. Recently acquired HCV incidence increased from 0.36/100 person-years to 1.25/100 person-years in MSM. The proportion of viremic patients decreased from 67.0% to 8.9%. MSM became the first group of viremic patients in 2018 (37.9%). Recently acquired hepatitis represented 59.2% of viremic MSM in 2018. DAA treatment uptake increased from 11.4% to 61.5%. More treatments were initiated in MSM in 2018 (41.2%) than in intravenous drug users (35.6%). In MSM, treatment at the acute phase represented 30.0% of treatments in 2018. Conclusions A major shift in HCV epidemiology was observed in PLWH in France from 2012 to 2018, leading to a unique situation in which the major group of HCV transmission in 2018 was MSM. Clinical Trials Registration. NCT02898987.
Published: 2020

14. Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

Author: Obry-Roguet, Véronique, Duvivier, Claudine, Lions, Caroline, Huleux, Thomas, Jacomet, Christine, Ferry, Tristan, Cheret, Antoine, Allavena, Clotilde, Bani-Sadr, Firouzé, Palich, Romain, Cabié, André, Pugliese, Pascal, Delobel, Pierre, Lamaury, Isabelle, Hustache-Mathieu, Laurent, Bregigeon, Sylvie, Makinson, Alain, Rey, David, Poizot-Martin, Isabelle, Hustache‐Mathieu, Laurent, Drobacheff‐Thiébaut, C., Foltzer, A., Bouiller, K., Hustache‐ Mathieu, L., Chirouze, C., LEPILLER, Q., Bozon, F., Babre, O, Brunel, A.S., Muret, P., Laurichesse, H., Lesens, O., Vidal, M., Mrozek, N., Aumeran, C., Baud, O., Corbin, V., Letertre‐Gibert, P., Casanova, S., Prouteau, J., Fabre, I., Curlier, E., Ouissa, R., Herrmann‐Storck, C., Tressieres, B., Bonijoly, T., Receveur, M.C., Boulard, F., Daniel, C., Clavel, C., Merrien, D., Perré, P., Guimard, T., Bollangier, O., Leautez, S., Morrier, M., Laine, L., Ader, F., Becker, A., Biron, F., Boibieux, A., Cotte, L., Miailhes, P., Perpoint, T., Roux, S., Triffault‐Fillit, C., Degroodt, S., Brochier, C., Valour, F., Chidiac, C., Ménard, A., Belkhir, A.Y., Colson, P., Dhiver, C., Madrid, A., Martin‐Degioanni, M., Meddeb, L., Mokhtari, M., Motte, A., Raoux, A., Ravaux, I., Tamalet, C., Tomei, C., Tissot Dupont, H., Zaegel‐Faucher, O., Obry‐Roguet, Véronique, Laroche, H, Orticoni, M., Soavi, M.J., Geneau de Lamarlière, P, Ressiot, E, Ducassou, M.J., Jaquet, I., Galie, S., Galinier, A., Martinet, P., Landon, M., Ritleng, A.S., Ivanova, A., Debreux, C., Poizot‐Martin, I., Abel, S., Cabras, O., Cuzin, L., Guitteaud, K., Illiaquer, M., Pierre‐François, S., Osei, L., Pasquier, J., Rome, K., Sidani, E., Turmel, JM, Varache, C., Atoui, N., Bistoquet, M., Delaporte, E., Le Moing, V., Meftah, N., Merle de Boever, C., Montes, B., Montoya Ferrer, A., Tuaillon, E., Reynes, J., André, M., Boyer, L., Bouillon, MP., Delestan, M., Rabaud, C., May, T., Hoen, B., Bernaud, C., Billaud, E., Biron, C., Bonnet, B., Bouchez, S., Boutoille, D., Brunet‐Cartier, C., Deschanvres, C., Hall, N., Morineau, P., Reliquet, V., Sécher, S., Cavellec, M., Soria, A., Paredes, E., Ferre, V., André‐Garnier, E., Rodallec, A., Lefebvre, M., Grossi, O., Aubry, O., Raffi, F., Breaud, S., Ceppi, C., Chirio, D., Cua, E., Dellamonica, P., Demonchy, E., De Monte, A., Durant, J., Etienne, C., Ferrando, S., Garraffo, R., Michelangeli, C., Mondain, V., Naqvi, A., Oran, N., Perbost, I., Pillet, S., Pradier, C., Prouvost‐Keller, B., Risso, K., Rio, V., Roger, PM., Rosenthal, E., Sausse, S., Touitou, I., Wehrlen‐Pugliese, S., Zouzou, G., Hocqueloux, L., Prazuck, T., Gubavu, C., Sève, A., Maka, A., Boulard, C., Thomas, G., Lerolle, N., Landman, R., Joly, V., Ghosn, J., Rioux, C., Lariven, S., Gervais, A., Lescure, F.X., Matheron, S., Louni, F., Julia, Z., Mackoumbou‐Nkouka, C., Le Gac, S., Charpentier, C., Descamps, D., Peytavin, G., Yazdanpanah, Y., Amazzough, K., Benabdelmoumen, G., Bossi, P., Cessot, G., Charlier, C., Consigny, P.H., Danion, F., Dureault, A., Goesch, J., Guery, R., Henry, B., Jidar, K., Lanternier, F., Loubet, P., Lortholary, O., Louisin, C., Lourenco, J., Parize, P., Pilmis, B., Touam, F, Valantin, M.A., Tubiana, R., Agher, R, Seang, S., Schneider, L., Blanc, C., Katlama, C., Berger, J.L., N'guyen, Y., Lambert, D., Kmiec, I., Hentzien, M., Brunet, A., Brodard, V., Bani‐Sadr, Firouze, Tattevin, P., Revest, M., Souala, F., Baldeyrou, M., Patrat‐Delon, S., Chapplain, J.M., Bénézit, F., Dupont, M., Poinot, M., Maillard, A., Pronier, C., Lemaitre, F., Guennoun, C., Poisson‐Vanier, M., Jovelin, T., Sinteff, J.P., Arvieux, C., Botelho‐Nevers, E., Gagneux‐Brunon, A., Frésard, Anne, Ronat, V., Lucht, F., Fischer, P., Partisani, M., Cheneau, C., Priester, M, Batard, ML, Bernard‐Henry, C, de Mautort, E, Fafi‐Kremer, S., Alvarez, M., Biezunski, N., Debard, A., Delpierre, C., Lansalot, P., Lelievre, L., Martin‐Blondel, G., Piffaut, M., Porte, L., Saune, K., Ajana, F., Aïssi, E., Alcaraz, I., Baclet, V., Bocket, L., Boucher, A., Choisy, P., Lafon‐Desmurs, B., Meybeck, A., Pradier, M., Robineau, O., Viget, N., Valette, M., Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Tourcoing, Département des Maladies Infectieuses et Tropicales [CHU Gabriel-Montpied, Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], Pathogénie des Staphylocoques – Staphylococcal Pathogenesis, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Services des maladies infectieuses [CH Turcoing], Centre Hospitalier de Tourcoing, Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), Alliance for International medical Action (ALIMA), Service de Maladies Infectieuses et Tropicales [Fort-de-France, Martinique], CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France]-Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Service de Maladies Infectieuses [Nice], Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pointe-à-Pitre/Abymes [Guadeloupe], service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Universtié Yaoundé 1 [Cameroun]-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Laboratoire d'Ingénierie Circulation Transport (LICIT), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR)-École Nationale des Travaux Publics de l'État (ENTPE)-Université de Lyon, Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Universitaire de Besançon (CHU Besançon), Université libre de Bruxelles (ULB), Hôpital Gabriel Montpied, Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Clermont-Ferrand, Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), CHU Gabriel Montpied (CHU), CHU Clermont-Ferrand, CCLIN Sud-Est – Centre de Coordination de la Lutte contre les Infections Nosocomiales Sud-Est, Montpellier Research in Management (MRM), Université Montpellier 1 (UM1)-Université Paul-Valéry - Montpellier 3 (UPVM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Perpignan Via Domitia (UPVD)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université de Montpellier (UM), Laboratoire Traitement et Communication de l'Information (LTCI), Télécom ParisTech-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Equipe 15, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon], Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Neurobiologie, plasticité tissulaire et métabolisme énergétique (NPTME), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), CECIL, Space Research Institute of the Russian Academy of Sciences (IKI), Russian Academy of Sciences [Moscow] (RAS), Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre IRD de Montpellier (IRD), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Bell Labs (BELL), Lucent Technologies, Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Centre hospitalier universitaire de Nantes (CHU Nantes), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Service des maladies infectieuses et tropicales [CHU Nantes], Plant Biomechanics Group, Botanischer Garten, Albert-Ludwigs-Universität Freiburg, Service de virologie [CHU Nantes], Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, Public Health Department, Hôpital de l'Archet, Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Infectious Diseases Department, Université Montpellier 1 (UM1), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Régional de recherche et de Formation à la prise en charge Clinique de Fann (CRCF), CHNU Fann, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Etudes Lasers Intenses et Applications (CELIA), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Pathogénie des infections systémiques (UMR_S 570), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses [CHU Pitié-Salêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Laboratoire d'aérologie (LA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Centre National de la Recherche Scientifique (CNRS), McGill University = Université McGill [Montréal, Canada], Service des maladies infectieuses et réanimation médicale, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôpitaux Universitaires de Strasbourg (HUS), Service de pneumologie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], CHU Pontchaillou [Rennes], SEV, Groupe d'Etudes et de Contrôle des Variétés et des Semences (GEVES), Service de virologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), University Hospital and University Jean Monnet, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Génomique métabolique (UMR 8030), Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Virologie et pathogenèse virale (VPV), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut Pasteur [Paris] (IP), Centre Hospitalier Gustave Dron [Tourcoing], Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) (EA 7327), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Département d'Hématologie Clinique [CHU Nantes] (Hôtel-Dieu), Hôtel-Dieu de Nantes-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Maladies infectieuses et tropicales dans la Caraïbe (MAITC EA 4537), CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de la Martinique [Fort de France]-Université des Antilles (UA), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre de Physiopathologie Toulouse Purpan (CPTP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Dermatologie et Maladies infectieuses [Pointe-à-Pitre], CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre de Gestion du Risque Infectieux Nosocomial [Pointe-à-Pitre] (CGRIN), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Infectious and Tropical Diseases Department [Montpellier], Institut de Recherche pour le Développement (IRD)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM), Dat'AIDS study group: C Drobacheff-Thiébaut, A Foltzer, K Bouiller, C Chirouze, Q Lepiller, F Bozon, O Babre, A S Brunel, P Muret, H Laurichesse, O Lesens, M Vidal, N Mrozek, C Aumeran, O Baud, V Corbin, P Letertre-Gibert, S Casanova, J Prouteau, I Fabre, E Curlier, R Ouissa, C Herrmann-Storck, B Tressieres, T Bonijoly, M C Receveur, F Boulard, C Daniel, C Clavel, D Merrien, P Perré, T Guimard, O Bollangier, S Leautez, M Morrier, L Laine, F Ader, A Becker, F Biron, A Boibieux, L Cotte, P Miailhes, T Perpoint, S Roux, C Triffault-Fillit, S Degroodt, C Brochier, F Valour, C Chidiac, A Ménard, A Y Belkhir, P Colson, C Dhiver, A Madrid, M Martin-Degioanni, L Meddeb, M Mokhtari, A Motte, A Raoux, I Ravaux, C Tamalet, C Toméi, H Tissot Dupont, O Zaegel-Faucher, H Laroche, M Orticoni, M J Soavi, P Geneau de Lamarlière, E Ressiot, M J Ducassou, I Jaquet, S Galie, A Galinier, P Martinet, M Landon, A S Ritleng, A Ivanova, C Debreux, S Abel, O Cabras, L Cuzin, K Guitteaud, M Illiaquer, S Pierre-François, L Osei, J Pasquier, K Rome, E Sidani, J M Turmel, C Varache, N Atoui, M Bistoquet, E Delaporte, V Le Moing, N Meftah, C Merle de Boever, B Montes, A Montoya Ferrer, E Tuaillon, J Reynes, M André, L Boyer, M P Bouillon, M Delestan, C Rabaud, T May, B Hoen, C Bernaud, E Billaud, C Biron, B Bonnet, S Bouchez, D Boutoille, C Brunet-Cartier, C Deschanvres, N Hall, T Jovelin, P Morineau, V Reliquet, S Sécher, M Cavellec, A Soria, E Paredes, V Ferré, E André-Garnier, A Rodallec, M Lefebvre, O Grossi, O Aubry, F Raffi, S Breaud, C Ceppi, D Chirio, E Cua, P Dellamonica, E Demonchy, A De Monte, J Durant, C Etienne, S Ferrando, R Garraffo, C Michelangeli, V Mondain, A Naqvi, N Oran, I Perbost, S Pillet, C Pradier, B Prouvost-Keller, K Risso, V Rio, P M Roger, E Rosenthal, S Sausse, I Touitou, S Wehrlen-Pugliese, G Zouzou, L Hocqueloux, T Prazuck, C Gubavu, A Sève, A Maka, C Boulard, G Thomas, C Goujard, Y Quertainmont, E Teicher, N Lerolle, O Deradji, A Barrail-Tran, R Landman, V Joly, J Ghosn, C Rioux, S Lariven, A Gervais, F X Lescure, S Matheron, F Louni, Z Julia, C Mackoumbou-Nkouka, S Le Gac, C Charpentier, D Descamps, G Peytavin, Y Yazdanpanah, K Amazzough, G Benabdelmoumen, P Bossi, G Cessot, C Charlier, P H Consigny, F Danion, A Dureault, J Goesch, R Guery, B Henry, K Jidar, F Lanternier, P Loubet, O Lortholary, C Louisin, J Lourenco, P Parize, B Pilmis, F Touam, M A Valantin, R Tubiana, R Agher, S Seang, L Schneider, C Blanc, C Katlama, J L Berger, Y N'Guyen, D Lambert, I Kmiec, M Hentzien, A Brunet, V Brodard, P Tattevin, M Revest, F Souala, M Baldeyrou, S Patrat-Delon, J M Chapplain, F Benezit, M Dupont, M Poinot, A Maillard, C Pronier, F Lemaitre, C Guennoun, M Poisson-Vanier, T Jovelin, J P Sinteff, C Arvieux, E Botelho-Nevers, A Gagneux-Brunon, A Frésard, V Ronat, F Lucht, P Fischer, M Partisani, C Cheneau, M Priester, M L Batard, C Bernard-Henry, E de Mautort, S Fafi-Kremer, M Alvarez, N Biezunski, A Debard, C Delpierre, P Lansalot, L Lelièvre, G Martin-Blondel, M Piffaut, L Porte, K Saune, F Ajana, E Aïssi, I Alcaraz, V Baclet, L Bocket, A Boucher, P Choisy, B Lafon-Desmurs, A Meybeck, M Pradier, O Robineau, N Viget, M Valette., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Institut Pasteur [Paris], Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Université Paul-Valéry - Montpellier 3 (UPVM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Perpignan Via Domitia (UPVD)-Université Montpellier 1 (UM1)-Groupe Sup de Co Montpellier (GSCM) - Montpellier Business School-Université de Montpellier (UM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Météo France-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, and Dupuis, Christine
Subjects: 0301 basic medicine, Pediatrics, medicine.medical_specialty, MESH: Sarcoma, Kaposi* / epidemiology, [SDV]Life Sciences [q-bio], 030106 microbiology, HIV Infections, Dermatology, Skin Infectiology, Venereology and Sexual Health, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), medicine, Humans, MESH: HIV Infections* / complications, 030212 general & internal medicine, Sarcoma, Kaposi, Retrospective Studies, Response rate (survey), MESH: Acquired Immunodeficiency Syndrome, MESH: Herpesvirus 8, Human, Acquired Immunodeficiency Syndrome, MESH: Humans, business.industry, Kaposi sarcoma, HIV, Retrospective cohort study, MESH: Retrospective Studies, MESH: HIV Infections* / drug therapy, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], medical dermatology, Regimen, Infectious Diseases, Clinical research, clinical research, Herpesvirus 8, Human, Cohort, oncology, Original Article, Sarcoma, business, Viral load, MESH: HIV Infections* / epidemiology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Background - Although antiretroviral therapy (ART) has reduced the risk of Kaposi sarcoma (KS), KS cases still occur in HIV-infected people. Objective - To describe all KS cases observed between 2010 and 2015 in a country with high ART coverage. Methods - Retrospective study using longitudinal data from 44 642 patients in the French Dat'AIDS multicenter cohort. Patients' characteristics were described at KS diagnosis according to ART exposure and to HIV-plasma viral load (HIV-pVL) (≤50 or >50) copies/mL. Results - Among the 209 KS cases diagnosed during the study period, 33.2% occurred in ART naïve patients, 17.3% in ART-experienced patients and 49.5% in patients on ART, of whom 23% for more than 6 months. Among these patients, 24 (11.5%) had HIV-pVL ≤50 cp/mL, and 16 (66%) were treated with a boosted-PI-based regimen. The distribution of KS localization did not differ by ART status nor by year of diagnosis. Limitations - Data on human herpesvirus 8, treatment modalities for KS and response rate were not collected. Conclusion - Half of KS cases observed in the study period occurred in patients not on ART, reflecting the persistence of late HIV diagnosis. Factors associated with KS in patients on ART with HIV-pVL ≤50 cp/mL remain to be explored.
Published: 2020

15. Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat’AIDS Cohort Study

Author: Demontès, Marie, Eymard Duvernay, Sabrina, Allavena, Clotilde, Jovelin, Thomas, Reynes, Jacques, Hentzien, Maxime, Ravaux, Isabelle, Delobel, Pierre, Bregigeon, Sylvie, Rey, David, Ferry, Tristan, Gagneux-Brunon, Amandine, Robineau, Olivier, Pugliese, Pascal, Duvivier, Claudine, Cabié, André, Chirouze, Catherine, Jacomet, Christine, Lamaury, Isabelle, Merrien, Dominique, Hoen, Bruno, Hocqueloux, Laurent, Cheret, Antoine, Katlama, Christine, Arvieux, Cédric, Krolak-Salmon, Pierre, Makinson, Alain, Drobacheff-Thiébaut, C, Foltzer, A, Bouiller, K, Hustache- Mathieu, L, Chirouze, C, Lepiller, Q, Bozon, F, Babre, O, Brunel, S, Muret, P, Laurichesse, H, Lesens, O, Vidal, M, Mrozek, N, Aumeran, C, Baud, O, Corbin, V, Letertre-Gibert, P, Casanova, S, Prouteau, J, Jacomet, C, Lamaury, I, Fabre, I, Curlier, E, Ouissa, R, Herrmann-Storck, C, Tressieres, B, Bonijoly, T, Receveur, C, Boulard, F, Daniel, C, Clavel, C, Merrien, D, Perré, P, Guimard, T, Bollangier, O, Leautez, S, Morrier, M, Laine, L, Ader, F, Becker, A, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Miailhes, P, Perpoint, T, Roux, S, Triffault-Fillit, C, Degroodt, S, Brochier, C, Valour, F, Chidiac, C, Ménard, A, Belkhir, Y, Colson, P, Dhiver, C, Madrid, A, Martin-Degiovani, M, Meddeb, L, Mokhtari, M, Motte, A, Raoux, A, Ravaux, I, Tamalet, C, Toméi, C, Tissot Dupont, H, Brégigeon, S, Zaegel-Faucher, O, Obry-Roguet, V, Laroche, H, Orticoni, M, Soavi, J, Geneau de Lamarlière, P, Ressiot, E, Ducassou, J, Jaquet, I, Galie, S, Galinier, A, Martinet, P, Landon, M, Ritleng, S, Ivanova, A, Debreux, C, Lions, C, Poizot-Martin, I, Abel, S, Cabras, O, Cuzin, L, Guitteaud, K, Illiaquer, M, Pierre-François, S, Osei, L, Pasquier, J, Rome, K, Sidani, E, Turmel, M, Varache, C, Cabié, A, Atoui, N, Bistoquet, M, Delaporte, E, Le Moing, V, Makinson, A, Meftah, N, Merle de Boever, C, Montes, B, Montoya Ferrer, A, Tuaillon, E, Reynes, J, André, M, Boyer, L, Bouillon, P, Delestan, M, Rabaud, C, May, T, Hoen, B, Allavena, C, Bernaud, C, Billaud, E, Biron, C, Bonnet, B, Bouchez, S, Boutoille, D, Brunet-Cartier, C, Deschanvres, C, Hall, N, Jovelin, T, Morineau, P, Reliquet, V, Sécher, S, Cavellec, M, Soria, A, Ferré, V, André-Garnier, E, Rodallec, A, Lefebvre, M, Grossi, O, Aubry, O, Raffi, F, Pugliese, P, Breaud, S, Ceppi, C, Chirio, D, Cua, E, Dellamonica, P, Demonchy, E, de Monte, A, Durant, J, Etienne, C, Ferrando, S, Garraffo, R, Michelangeli, C, Mondain, V, Naqvi, A, Oran, N, Perbost, I, Pillet, S, Pradier, C, Prouvost-Keller, B, Risso, K, Rio, V, Roger, P, Rosenthal, E, Sausse, S, Touitou, I, Wehrlen-Pugliese, S, Zouzou, G, Hocqueloux, L, Prazuck, T, Gubavu, C, Sève, A, Maka, A, Boulard, C, Thomas, G, Cheret, A, Goujard, C, Quertainmont, Y, Teicher, E, Lerolle, N, Deradji, O, Barrail-Tran, A, Landman, R, Joly, V, Ghosn, J, Rioux, C, Lariven, S, Gervais, A, Lescure, F, Matheron, S, Louni, F, Julia, Z, Mackoumbou-Nkouka, C, Le Gac, S, Charpentier, C, Descamps, D, Peytavin, G, Yazdanpanah, Y, Amazzough, K, Avettand-Fenoël, V, Benabdelmoumen, G, Bossi, P, Cessot, G, Charlier, C, Consigny, P, Danion, F, Dureault, A, Duvivier, C, Goesch, J, Guery, R, Henry, B, Jidar, K, Lanternier, F, Loubet, P, Lortholary, O, Louisin, C, Lourenco, J, Parize, P, Pilmis, B, Touam, F, Valantin, M, Tubiana, R, Agher, R, Seang, Sophie, Schneider, L, Palich, R, Blanc, C, Katlama, C, Berger, J, N’guyen, Y, Lambert, D, Kmiec, I, Hentzien, M, Brunet, A, Brodard, V, Bani-Sadr, F, Tattevin, P, Revest, M, Souala, F, Baldeyrou, M, Patrat-Delon, S, Chapplain, J, Benezit, F, Dupont, M, Poinot, M, Maillard, A, Pronier, C, Lemaitre, F, Guennoun, C, Poisson-Vanier, M, Sinteff, J, Arvieux, C, Botelho-Nevers, E, Gagneux-Brunon, A, Frésard, A, Ronat, V, Lucht, F, Fischer, P, Partisani, M, Cheneau, C, Priester, M, Batard, L, Bernard-Henry, C, de Mautort, E, Fafi-Kremer, S, Rey, D, Alvarez, M, Biezunski, N, Debard, A, Delpierre, C, Lansalot, P, Lelièvre, L, Martin-Blondel, G, Piffaut, M, Porte, L, Saune, K, Delobel, P, Ajana, F, Aïssi, E, Alcaraz, I, Baclet, V, Bocket, L, Boucher, A, Choisy, P, Huleux, T, Lafon-Desmurs, B, Meybeck, A, Pradier, M, Robineau, O, Viget, N, Valette, M, Hospices Civils de Lyon (HCL), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Université de Nantes (UN), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Reims (CHU Reims), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Pathogénie des Staphylocoques – Staphylococcal Pathogenesis, Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Université de Saint-Etienne, Service Universitaire des Maladies Infectieuses et du Voyageur [Tourcoing], Centre Hospitalier Tourcoing, Service de Maladies Infectieuses [Nice], Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Service de Maladies Infectieuses et Tropicales [Fort-de-France, Martinique], CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France]-Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Département des Maladies Infectieuses et Tropicales [CHU Gabriel-Montpied, Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Pointe-à-Pitre/Abymes [Guadeloupe], Centre Hospitalier Compiègne-Noyon, Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles et de la Guyane (UAG), Centre Hospitalier Régional d'Orléans (CHR), Services des maladies infectieuses [CH Turcoing], Centre Hospitalier de Tourcoing, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et réanimation médicale, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Besançon (CHU Besançon), Université libre de Bruxelles (ULB), Hôpital Gabriel Montpied, Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Clermont-Ferrand, Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA), CCLIN Sud-Est – Centre de Coordination de la Lutte contre les Infections Nosocomiales Sud-Est, Service de Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville, Laboratoire Traitement et Communication de l'Information (LTCI), Télécom ParisTech-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Institut de biologie et chimie des protéines [Lyon] (IBCP), Hôpital de la Croix-Rousse [CHU - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Equipe 15, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Laboratoire de Mécanique et Technologie (LMT), École normale supérieure - Cachan (ENS Cachan)-Centre National de la Recherche Scientifique (CNRS), Centre interrégional de référence Rhône-Alpes - Auvergne des infections ostéo-articulaires complexes, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Assistance Publique - Hôpitaux de Marseille (APHM), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Space Research Institute of the Russian Academy of Sciences (IKI), Russian Academy of Sciences [Moscow] (RAS), DDSIS 76, Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre IRD de Montpellier (IRD), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Bell Labs (BELL), Lucent Technologies, Centre hospitalier universitaire de Nantes (CHU Nantes), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Université Clermont Auvergne (UCA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service des maladies infectieuses et tropicales [CHU Nantes], Océan du Large et Variabilité Climatique (OLVAC), Laboratoire d'études en Géophysique et océanographie spatiales (LEGOS), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Observatoire Midi-Pyrénées (OMP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Plant Biomechanics Group, Botanischer Garten, Albert-Ludwigs-Universität Freiburg, Hôtel-Dieu de Nantes, Service de virologie [CHU Nantes], Département Etude des Réacteurs (DER), CEA-Direction des Energies (ex-Direction de l'Energie Nucléaire) (CEA-DES (ex-DEN)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, Public Health Department, Hôpital de l'Archet, Institut de génétique humaine (IGH), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Infectious Diseases Department, Université Montpellier 1 (UM1), Environnements et Paléoenvironnements OCéaniques (EPOC), Observatoire aquitain des sciences de l'univers (OASU), Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-École pratique des hautes études (EPHE)-Centre National de la Recherche Scientifique (CNRS), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Régional de recherche et de Formation à la prise en charge Clinique de Fann (CRCF), CHNU Fann, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Etudes Lasers Intenses et Applications (CELIA), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Centre National de la Recherche Scientifique (CNRS)-Université de Lille, Sciences et Technologies, Laboratoire de Virologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Pathogénie des infections systémiques (UMR_S 570), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Service des maladies infectieuses [CHU Pitié-Salêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], McGill University, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôpitaux Universitaires de Strasbourg (HUS), Service de pneumologie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Centre de Physique des Particules de Marseille (CPPM), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Aix Marseille Université (AMU), CHU Pontchaillou [Rennes], SEV, Groupe d'Etudes et de Contrôle des Variétés et des Semences (GEVES), Service de virologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], CHU Saint-Etienne, University Hospital and University Jean Monnet, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Laboratoire de Virologie [Strasbourg], Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, CHU de Fort de France, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Université de Montpellier (UM), Service des Maladies Infectieuses et Tropicales [Hôpital de la Conception] (SMIT), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Centre de Physiopathologie Toulouse Purpan (CPTP - U1043 INSERM - UMR5282 CNRS - UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Strasbourg, Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet [Saint-Étienne] (UJM), Centre d'investigation clinique Antilles-Guyane (CIC - Antilles Guyane), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU de la Martinique [Fort de France]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], CHD Vendee (La Roche Sur Yon), Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre de Physiopathologie Toulouse Purpan (CPTP), Pathogénie des Staphylocoques – Staphylococcal Pathogenesis (StaPath), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de la Martinique [Fort de France]-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service des Maladies Infectieuses et Tropicales [CHU Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Centre Hospitalier Régional d'Orléans (CHRO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Jean Monnet - Saint-Étienne (UJM), Institut Pasteur [Paris] (IP), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre Médical de l'Institut Pasteur, Service des maladies infectieuses et réanimation médicale [Rennes], Département Maladies Infectieuses et Tropicales, Hôpital Universitaire, Montpellier, France, Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire Marseille, CHU Marseille, School of Civil and Environmental Engineering [Sydney], University of New South Wales [Sydney] (UNSW), Laboratoire d'Ingénierie Circulation Transport (LICIT UMR TE ), École Nationale des Travaux Publics de l'État (ENTPE)-Université de Lyon-Université Gustave Eiffel, Institut Cochin (IC UM3 (UMR 8104 / U1016)), CHU de la Martinique [Fort de France], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Clermont-Ferrand, Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp] (THERAVIR), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
Subjects: Male, 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, multimorbidity, [SDV]Life Sciences [q-bio], HIV Infections, comorbidities, elderly, Cachexia, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Diabetes mellitus, medicine, Humans, 030212 general & internal medicine, Aged, 2. Zero hunger, Acquired Immunodeficiency Syndrome, business.industry, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, aging, virus diseases, HIV, medicine.disease, 030112 virology, Comorbidity, Obesity, CD4 Lymphocyte Count, 3. Good health, Cross-Sectional Studies, Infectious Diseases, Cohort, Coinfection, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Cohort study
Abstract: Background We assessed prevalence of multimorbidity (MM) according to year of human immunodeficiency virus (HIV) diagnosis in elderly people living with HIV (PLWH). Methods This was a cross-sectional study of MM in PLWH aged ≥70 years from the Dat’AIDS French multicenter cohort. MM was defined as at least 3 coexistent morbidities of high blood pressure, diabetes mellitus, osteoporosis, non-AIDS cancer, chronic renal failure, cardiovascular and cerebrovascular disease, obesity, undernutrition, or hypercholesterolemia. Logistic regression models evaluated the association between MM and calendar periods of HIV diagnosis (1983–1996, 1997–2006, and 2007–2018). The secondary analysis evaluated MM as a continuous outcome, and a sensitivity analysis excluded PLWH with nadir CD4 count Results Between January 2017 and September 2018, 2476 PLWH were included. Median age was 73 years, 75% were men, median CD4 count was 578 cells/μL, and 94% had controlled viremia. MM prevalence was 71%. HBP and hypercholesterolemia were the most prevalent comorbidities. After adjustment for age, gender, smoking status, hepatitis C and hepatitis B virus coinfection, group of exposure, nadir CD4 count, CD4:CD8 ratio, and last CD4 level, calendar period of diagnosis was not associated with MM (P = .169). MM was associated with older age, CD4/CD8 ratio Conclusions MM prevalence was high and increased with age, low CD4/CD8 ratio, and nadir CD4 count
Published: 2019

16. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM)

Author: Liégeois, Florian, Eymard-Duvernay, Sabrina, Boyer, S., Maradan, G., Kouanfack, C., Domyeum, J., Boyer, V., Mpoudi-Ngole, E., Spire, B., Delaporte, E., Vidal, Laurent, Kuaban, C., Laurent, Christian, and Evolcam Study Group
Subjects: virological outcome, Africa, antiretroviral, effectiveness, HIV
Abstract: Objectives In terms of HIV infection, western and central Africa is the second most affected region world-wide, and the gap between the regional figures for the testing and treatment cascade and the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets is particularly worrying. We assessed the prevalence of virological suppression in patients routinely treated in 19 hospitals in Cameroon. Methods A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in the Centre and Littoral regions. The prevalences of virological suppression (mL) were compared among all 19 hospitals using the chi(2) test. Potential individual and health care-related determinants of virological suppression were assessed using multivariate logistic regression models. Results A total of 1700 patients (74% women; median age 41 years; median time on ART 3.7 years) were included in the study. The prevalence of virological suppression was 82.4% overall (95% confidence interval 80.5-84.2%). It ranged from 57.1 to 97.4% according to the individual hospital (P < 0.001). After adjustment, virological suppression was associated with age, CD4 cell count at ART initiation, disclosure of HIV status to family members, interruption of ART for more than two consecutive days, and location of patient's residence and hospital (rural/urban). These factors did not explain the heterogeneity of virological suppression between the study hospitals (P < 0.001). Conclusions The overall prevalence of virological suppression was reassuring. Nevertheless, the heterogeneity of virological suppression among hospitals highlights that, in addition to programme-level data, health facility-level data are crucial in order to tailor the national AIDS programme's interventions with a view to achieving the third UNAIDS 90 target.
Published: 2019

17. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).

Author: Liégeois, F, Eymard‐Duvernay, S, Boyer, S, Maradan, G, Kouanfack, C, Domyeum, J, Boyer, V, Mpoudi‐Ngolé, E, Spire, B, Delaporte, E, Vidal, L, Kuaban, C, Laurent, C, Ambani, A, Ndalle, O, Momo, P, Tong, C, March, L, Mora, M, and Sagaon Teyssier, L
Subjects: ANTIRETROVIRAL agents, CHI-squared test, CONFIDENCE intervals, HEALTH facilities, HIV infections, IMMUNIZATION, MEDICAL protocols, MULTIVARIATE analysis, RNA, SURVEYS, LOGISTIC regression analysis, VIRAL load, EXTENDED families, DISEASE prevalence, CROSS-sectional method, CD4 lymphocyte count
Abstract: Objectives: In terms of HIV infection, western and central Africa is the second most affected region world‐wide, and the gap between the regional figures for the testing and treatment cascade and the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90–90–90 targets is particularly worrying. We assessed the prevalence of virological suppression in patients routinely treated in 19 hospitals in Cameroon. Methods: A cross‐sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in the Centre and Littoral regions. The prevalences of virological suppression (<1000 HIV‐1 RNA copies/mL) were compared among all 19 hospitals using the χ2 test. Potential individual and health care‐related determinants of virological suppression were assessed using multivariate logistic regression models. Results: A total of 1700 patients (74% women; median age 41 years; median time on ART 3.7 years) were included in the study. The prevalence of virological suppression was 82.4% overall (95% confidence interval 80.5–84.2%). It ranged from 57.1 to 97.4% according to the individual hospital (P < 0.001). After adjustment, virological suppression was associated with age, CD4 cell count at ART initiation, disclosure of HIV status to family members, interruption of ART for more than two consecutive days, and location of patient's residence and hospital (rural/urban). These factors did not explain the heterogeneity of virological suppression between the study hospitals (P < 0.001). Conclusions: The overall prevalence of virological suppression was reassuring. Nevertheless, the heterogeneity of virological suppression among hospitals highlights that, in addition to programme‐level data, health facility‐level data are crucial in order to tailor the national AIDS programme's interventions with a view to achieving the third UNAIDS 90 target. [ABSTRACT FROM AUTHOR]
Published: 2019
Full Text: View/download PDF

18. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ ESTHER trial in Cameroon.

Author: Meresse, M, March, L, Kouanfack, C, Bonono, R‐C, Boyer, S, Laborde‐Balen, G, Aghokeng, A, Suzan‐Monti, M, Delaporte, E, Spire, B, Carrieri, M‐P, and Laurent, C
Subjects: CHI-squared test, CONFIDENCE intervals, DRUG resistance, DRUGS, HIV-positive persons, LONGITUDINAL method, GENETIC mutation, PATIENT compliance, RESEARCH funding, U-statistics, VIRAL load, ANTIRETROVIRAL agents, PROPORTIONAL hazards models, ODDS ratio
Abstract: Objectives The emergence of HIV drug resistance is a crucial issue in Africa, where second-line antiretroviral therapy ( ART) is limited, expensive and complex. We assessed the association between adherence patterns and resistance emergence over time, using an adherence measure that distinguishes low adherence from treatment interruptions, in rural Cameroon. Methods We performed a cohort study among patients receiving nonnucleoside reverse transcriptase inhibitor ( NNRTI)-based ART in nine district hospitals, using data from the Stratall trial (2006−2010). Genotypic mutations associated with antiretroviral drug resistance were assessed when 6-monthly HIV viral loads were > 5000 HIV-1 RNA copies/mL. ART adherence data were collected using face-to-face questionnaires. Combined indicators of early (1−3 months) and late (6 months to t − 1; t is the time point when the resistance had been detected) adherence were constructed. Multivariate logistic regression and Cox models were used to assess the association between adherence patterns and early (at 6 months) and late (after 6 months) resistance emergence, respectively. Results Among 456 participants (71% women; median age 37 years), 45 developed HIV drug resistance (18 early and 27 late). Early low adherence (< 80%) and treatment interruptions (> 2 days) were associated with early resistance [adjusted odds ratio (95% confidence interval) 8.51 (1.30-55.61) and 5.25 (1.45-18.95), respectively]. Early treatment interruptions were also associated with late resistance [adjusted hazard ratio (95% confidence interval) 3.72 (1.27-10.92)]. Conclusions The emergence of HIV drug resistance on first-line NNRTI-based regimens was associated with different patterns of adherence over time. Ensuring optimal early adherence through specific interventions, adequate management of drug stocks, and viral load monitoring is a clinical and public health priority in Africa. [ABSTRACT FROM AUTHOR]
Published: 2014
Full Text: View/download PDF

19. High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.

Author: Laurent, C., Bourgeois, A., Mpoudi-Ngolé, E., Kouanfack, C., Ciaffi, L., Nkoué, N., Mougnutou, R., Calmy, A., Koulla-Shiro, S., Ducos, J., and Delaporte, E.
Subjects: HIV-positive persons, ANTIVIRAL agents, VIRAL hepatitis, BLOOD plasma, HEPATITIS C virus, AMINOTRANSFERASES
Abstract: Objectives To investigate the presence of hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA in HIV-infected patients initiating antiretroviral therapy in Cameroon. Methods Baseline blood samples from 169 patients were tested retrospectively for hepatitis B surface antigens (HBsAg), anti-hepatitis B core (anti-HBc), anti-HCV and – if HBsAg or anti-HCV result was positive or indeterminate – for HBV DNA or HCV RNA, respectively, using the Cobas Ampliprep/Cobas TaqMan quantitative assay (Roche Diagnostics GmbH, Mannheim, Germany). Results HBV DNA was detected in 14 of the 18 patients with positive or indeterminate HBsAg results [8.3% of the total study population, 95% confidence interval (CI) 4.6–13.5]. The median HBV viral load was 2.47 × 107 IU/mL [interquartile range (IQR) 3680–1.59 × 108; range 270 to >2.2 × 108]. Twenty-one patients (12.4%, 95% CI 7.9–18.4) were found with HCV RNA (all with positive HCV serology). The median HCV viral load was 928 000 IU/mL (IQR 178 400–2.06 × 106; range 640–5.5 × 106). No patient was co-infected with HBV and HCV. In multivariate analysis, HCV co-infection was associated with greater age [≥45 years vs. <45 years, odds ratio (OR) 11.89, 95% CI 3.49–40.55, P<0.001] and abnormal serum alanine aminotransferase level [≥1.25 × upper limit of normal (ULN) vs. <1.25 × ULN, OR 7.81, 95% CI 1.54–39.66, P=0.01]; HBV co-infection was associated with abnormal serum aspartate aminotransferase level (OR 4.33, 95% CI 1.32–14.17, P=0.02). Conclusions These high rates of active HBV and HCV co-infections in HIV-positive Cameroonian patients requiring antiretroviral therapy underline the need to promote: (i) screening for HBV and HCV before treatment initiation; (ii) accessibility to tenofovir (especially in HBV-endemic African countries); and (iii) accessibility to treatment for HBV and HCV infections. [ABSTRACT FROM AUTHOR]
Published: 2010
Full Text: View/download PDF

20. Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal.

Author: Seck, K, Samb, N, Tempesta, S, Mulanga-Kabeya, C, Henzel, D, Sow, P S, Coll-Seck, A, Mboup, S, Ndoye, I, and Delaporte, E
Subjects: RNA analysis, CERVIX uteri, COMPARATIVE studies, HIV, RESEARCH methodology, MEDICAL cooperation, REGRESSION analysis, RESEARCH, VAGINA, VIRAL physiology, EVALUATION research, DISEASE prevalence, CROSS-sectional method, HIV seroconversion, DISEASE progression, ODDS ratio
Abstract: Objectives: To assess the risk determinants and prevalence of cervicovaginal shedding of HIV-1 and HIV-2 among women in Dakar, Senegal.Methods: We conducted a cross sectional study of 153 HIV seropositive female sex workers (FSW) and another 142 HIV seropositive women attending an infectious diseases unit, based on an interview, physical examination, and laboratory screening for major sexually transmitted infections (STI). Cervicovaginal lavage fluid was tested for HIV-RNA by means of nested PCR. Links between cervicovaginal shedding of HIV-1 and HIV-2 and sociodemographic, clinical, and laboratory variables were identified by using odd ratios and 95% confidence intervals. Logistic regression analysis was used to identify independent links with HIV shedding.Results: The detection rate of HIV-RNA in cervicovaginal lavage fluid was low among FSW, with no difference between HIV-1 (7/90: 8%) and HIV-2 (3/48: 6%). The rate was far higher among the other women (41%, 48/117; 33%, 7/21 for HIV-1 and HIV-2, respectively). In multivariate analysis, high plasma viral load (>40 000 copies/ml) (AOR = 2.4 (1.0-5.6) p = 0.04) and basic vaginal pH (AOR = 2.2 (1.3-3.7) p = 0.002) were independently associated with HIV-1 shedding. For HIV-2 a CD4 count < 200 cells x 10(6)/l was the only factor associated with the shedding of HIV-2 (AOR = 9.0 (0.9-93)). The genital shedding rate was higher with HIV-1 than with HIV-2 (OR = 2.1 (0.9-4.8), but this difference disappeared after adjustment for the CD4+ cell count (AOR = 1.2 (0.5-2.9)).Conclusion: Advanced disease stage and immunosuppression are the major risk determinants for shedding of both HIV-1 and HIV-2. Basic vaginal pH is also a risk determinant for HIV-1 shedding. [ABSTRACT FROM AUTHOR]
Published: 2001
Full Text: View/download PDF

21. Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays.

Author: Peeters, M., Aghokeng, A. F., and Delaporte, E.
Subjects: *DRUG resistance, *HIV, *VIRAL load, *HIV infections, *TREATMENT effectiveness
Abstract: Clin Microbiol Infect 2010; 16: 1525-1531 Abstract The tremendous diversity of human immunodeficiency virus (HIV)-1 strains circulating worldwide has an important impact on almost all aspects of the management of this infection, from the identification of infected persons, through treatment efficacy and monitoring, and prevention strategies such as vaccine design. The areas where HIV-1 genetic diversity is highest are those where the majority of patients in need of treatment and biological monitoring live. With increased access to treatment in these areas, it is expected that the demand for monitoring tools such as viral load assays and resistance tests will also increase, and their reliability will be critical. Regular updates of these assays during the last two decades have aimed at improving their performances in different ways that include their reliability with different HIV-1 strains. We here review to what extent HIV-1 genetic diversity still limits or not the use of currently available viral load and resistance tests. [ABSTRACT FROM AUTHOR]
Published: 2010
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

21 results on '"Delaporte, E."'

1. Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo.

2. Susceptibility to transmitting HIV in patients initiating antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial).

3. Task shifting HIV care in rural district hospitals in Cameroon: evidence of comparable antiretroviral treatment-related outcomes between nurses and physicians in the Stratall ANRS/ESTHER trial.

4. Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis.

5. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.

6. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment.

7. Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002.

8. [Prevalence of hepatitis B and C virus, HTLV-1 and HIV in type B lymphoproliferative syndromes in Gabon].

9. Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny.

10. Reactivities of antibodies to HIV and SIV in human sera in Kenya, Gabon, and Ghana.

11. Impact à long terme des traitements antirétroviraux en Afrique, état des connaissances

12. Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

13. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018

14. Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

15. Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat’AIDS Cohort Study

16. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM)

17. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).

18. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ ESTHER trial in Cameroon.

19. High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.

20. Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal.

21. Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays.

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

21 results on '"Delaporte, E."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources